$13.33
-0.02-0.15%
Last update: Nov 10, 4:26 PM
Latigo Biotherapeutics Inc
LTGONASDAQ
The average analyst price target for Latigo Biotherapeutics is $45.33, 235.3% above the current price. Of 3 analysts, 3 rate it Buy. Targets range from $36 to $50. The latest change came on Sep 1, 2026, when Leerink Partners initiated coverage of Latigo Biotherapeutics with an Outperform rating and a $36 price target.
Price Target Range — 1 Quarters
Analyst Consensus — 3 Analysts
Rating Trend — Last 9 Months
